CBLI - Cleveland BioLabs, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Cleveland BioLabs, Inc.

73 High Street
Buffalo, NY 14203
United States
716-849-6810
http://www.cbiolabs.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 12

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Yakov N. Kogan Ph.D., MBA	Chief Exec. Officer and Interim Principal Financial Officer	287.47k	N/A	1973
Dr. Langdon L. Miller M.D.	Pres and Chief Medical Officer	193.57k	N/A	1954
Dr. Andrei V. Gudkov Ph.D., D.Sci.	Chief Scientific Officer	N/A	N/A	1956
Dr. Ann Lenich Hards Ph.D.	Exec. VP of Regulatory Affairs	N/A	N/A	N/A
Dr. Andrei Purmal Ph.D.	VP of Chemistry	N/A	N/A	N/A

Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Corporate Governance

Cleveland BioLabs, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.